Evidence map›Paper›PMID 33815288›Full record

ArticleFrontiers in endocrinology2021

NT3/TrkC Pathway Modulates the Expression of UCP-1 and Adipocyte Size in Human and Rodent Adipose Tissue.

María Bové, Fermi Monto, Paloma Guillem-Llobat, M Dolores Ivorra, M Antonia Noguera, Andrea Zambrano, M Salome Sirerol-Piquer, Ana Cristina Requena, Mauricio García-Alonso, Teresa Tejerina and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

María BovéDepartamento de Farmacología, Facultad de Farmacia, Universidad de Valencia, Valencia, Spain.
Fermi MontoDepartamento de Farmacología, Facultad de Farmacia, Universidad de Valencia, Valencia, Spain.
Paloma Guillem-LlobatDepartamento de Farmacología, Facultad de Farmacia, Universidad de Valencia, Valencia, Spain.
M Dolores IvorraDepartamento de Farmacología, Facultad de Farmacia, Universidad de Valencia, Valencia, Spain.
M Antonia NogueraDepartamento de Farmacología, Facultad de Farmacia, Universidad de Valencia, Valencia, Spain.
Andrea ZambranoDepartamento de Farmacología, Facultad de Farmacia, Universidad de Valencia, Valencia, Spain.
M Salome Sirerol-PiquerEstructura de Recerca Interdisciplinar en Biotecnologia i Biomedicina (ERI BIOTECMED), Universidad de Valencia, Valencia, Spain.
Ana Cristina RequenaDepartamento de Biología Celular, Biología Funcional y Antropología Física, Universidad de Valencia, Valencia, Spain.
Mauricio García-AlonsoServicio de Cirugía General y Aparato Digestivo, Hospital Clínico San Carlos, Madrid, Spain.
Teresa TejerinaServicio de Cirugía General y Aparato Digestivo, Hospital Clínico San Carlos, Madrid, Spain.
José T RealCIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain.
Isabel FariñasEstructura de Recerca Interdisciplinar en Biotecnologia i Biomedicina (ERI BIOTECMED), Universidad de Valencia, Valencia, Spain.
Pilar D'OconDepartamento de Farmacología, Facultad de Farmacia, Universidad de Valencia, Valencia, Spain.
Instituto de Biomedicina de Valencia · ESUniversitat de València · ESHospital Clínico San Carlos · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conclusions: NT3, mainly released by blood vessels, activates TrkC and regulates adipocyte differentiation and browning. Disruption of NT3/TrkC signaling conducts to hypertrophied white and brown adipocytes with reduced expression of the thermogenesis marker UCP-1.

Indexed as

Cell SizeSignal TransductionAdipocytesAdipose TissueAgedAgingAnimalsBiomarkersBlood VesselsBody WeightCell DifferentiationFemaleHumansLipolysisMaleMice, TransgenicBiomarkersReceptors, Adrenergic, betaReceptor, trkCUncoupling Protein 1adipocytesbeta-adrenoceptorsbrown adipose tissueneurotrophin-3tropomyosin-related kinase receptor CUCP-1white adipose tissue

Identifiers

PMID33815288
PMCPMC8015941
OpenAlexW3137134865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.